Geode Capital Management
ALXO icon

Geode Capital Management’s ALX Oncology ALXO Stock Holding History

Geode Capital Management’s Portfolio ALXO Stock Details ALXO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$5.77M Buy
2,787,809
+2,294,372
+465% +$4.11M ﹤0.01% 2838
2026
Q1 		$990K Buy
493,437
+139,741
+40% +$266K ﹤0.01% 3352
2025
Q4 		$400K Buy
353,696
+1,361
+0.4% +$2.06K ﹤0.01% 3676
2025
Q3 		$645K Buy
352,335
+36,914
+12% +$32K ﹤0.01% 3527
2025
Q2 		$131K Sell
315,421
-455,486
-59% -$230K ﹤0.01% 3996
2025
Q1 		$480K Buy
770,907
+30,801
+4% +$37K ﹤0.01% 3558
2024
Q4 		$1.24M Buy
740,106
+39,259
+6% +$60.3K ﹤0.01% 3292
2024
Q3 		$1.28M Buy
700,847
+441
+0.1% +$1.64K ﹤0.01% 3270
2024
Q2 		$4.22M Buy
700,406
+95,692
+16% +$1.18M ﹤0.01% 2823
2024
Q1 		$6.74M Buy
604,714
+19,680
+3% +$276K ﹤0.01% 2542
2023
Q4 		$8.71M Buy
585,034
+141,967
+32% +$1.35M ﹤0.01% 2417
2023
Q3 		$2.13M Sell
443,067
-1,231
-0.3% -$6.68K ﹤0.01% 3061
2023
Q2 		$3.34M Buy
444,298
+23,254
+6% +$152K ﹤0.01% 2912
2023
Q1 		$1.9M Buy
421,044
+8,735
+2% +$66.2K ﹤0.01% 3053
2022
Q4 		$4.65M Buy
412,309
+18,988
+5% +$213K ﹤0.01% 2708
2022
Q3 		$3.76M Buy
393,321
+13,121
+3% +$153K ﹤0.01% 2822
2022
Q2 		$3.08M Buy
380,200
+59,859
+19% +$652K ﹤0.01% 2958
2022
Q1 		$5.41M Sell
320,341
-19,505
-6% -$333K ﹤0.01% 2757
2021
Q4 		$7.3M Sell
339,846
-20,500
-6% -$884K ﹤0.01% 2658
2021
Q3 		$26.6M Buy
360,346
+82,069
+29% +$5.47M ﹤0.01% 1758
2021
Q2 		$15.2M Buy
278,277
+6,260
+2% +$375K ﹤0.01% 2159
2021
Q1 		$20.1M Buy
272,017
+91,149
+50% +$7.17M ﹤0.01% 1879
2020
Q4 		$15.6M Buy
180,868
+26,239
+17% +$1.58M ﹤0.01% 1881
2020
Q3 		$5.83M Buy
+154,629
New +$6.08M ﹤0.01% 2301

Other funds holding ALXO

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
VP
venBio Partners San Francisco, California $519M AUM 339.42% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
Blackstone Inc
Blackstone Inc New York $32.9B AUM 23.66% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
SCM
Silverarc Capital Management Boston, Massachusetts $962M AUM 524.64% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return

Geode Capital Management's ALXO Position: Q2 2026 in Review

Geode Capital Management increased its ALX Oncology (ALXO) stake by 465% in Q2 2026, buying an estimated $4.11M and bringing the position to 2,787,809 shares worth $5.77M. The position accounts for ﹤0.01% of the portfolio, ranked #2838.

Geode Capital Management first reported a position in ALXO in Q3 2020 and has held it in 24 quarters since. The position peaked at $26.6M in Q3 2021. 93 funds tracked by Wall St. Rank hold ALXO as of Q2 2026.

  • Geode Capital Management held 2,787,809 shares of ALX Oncology worth $5.77M as of Q2 2026.
  • Geode Capital Management bought 2,294,372 ALX Oncology shares in Q2 2026, an estimated $4.11M.
  • ALX Oncology made up ﹤0.01% of Geode Capital Management's portfolio in Q2 2026, its #2838 holding.
  • Geode Capital Management first reported a position in ALX Oncology in Q3 2020 and has held it in 24 quarters since.
  • Geode Capital Management's ALX Oncology position peaked at $26.6M in Q3 2021.
  • 93 funds tracked by Wall St. Rank held ALX Oncology as of Q2 2026.

Based on Geode Capital Management's 13F filing for Q2 2026, filed 12 Aug 2026.